Hormonal
Treatment with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduced incidence of dementia in patients with type 2 diabetes.
If you have Type 2 Diabetes, discuss GLP-1 receptor agonists (like liraglutide or semaglutide) with your doctor. This paper suggests these medications may lower your risk of developing dementia compared to other diabetes treatments. This is particularly relevant if you are at high cardiovascular risk.
We found that treatment with GLP-1 RAs was associated with a reduced incidence of dementia in patients with type 2 diabetes in three pooled RCTs and in a nationwide cohort.
Why this rating
Combines high-quality RCT data with a large, real-world nationwide registry, though dementia was not a prespecified endpoint in RCTs.
Source
Treatment with glucagon‐like peptide‐1 receptor agonists and incidence of dementia: Data from pooled double‐blind randomized controlled trials and nationwide disease and prescription registers
Caroline Holm Nørgaard et al. · Alzheimer s & Dementia Translational Research & Clinical Interventions · 2022
DOI 10.1002/trc2.12268
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →